Search research articles
Contact Us
Filters
Showing results (11-20 of 32) with videos related to
Page
of 4
Sort By:
BMJ Open
|
October 17, 2020
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
Jonas S Heitmann, Juliane S Walz, Martin Pflügler, et al.
Annals of Hematology
|
January 23, 2020
Identification of CD318 (CDCP1) as novel prognostic marker in AML
Jonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, et al.
Cancers
|
September 28, 2021
CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
Joseph Kauer, Fabian Vogt, Ilona Hagelstein, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2022
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
Joseph Kauer, Melanie Märklin, Martin Pflügler, et al.
Frontiers in Immunology
|
March 16, 2026
Generation and preclinical characterization of a novel bispecific CD19-TCRgammadelta antibody for the treatment of B cell acute lymphoblastic leukemia
Joseph Kauer, Fabian Vogt, Sebastian Hörner, et al.
Scientific Reports
|
December 5, 2019
CD105 (Endoglin) as negative prognostic factor in AML
Joseph Kauer, Karolin Schwartz, Claudia Tandler, et al.
Hematological Oncology
|
January 21, 2023
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma
Joseph Kauer, Lilli Sophie Sester, Katharina Kriegsmann, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2020
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
Joseph Kauer, Sebastian Hörner, Lukas Osburg, et al.
BMC Cancer
|
November 22, 2023
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
Joseph Kauer, Emma P Freundt, Anita Schmitt, et al.
Frontiers in Immunology
|
September 28, 2020
Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia
Melanie Märklin, Alexander R Fuchs, Claudia Tandler, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 32) with videos related to
Sort By:
Page
of 4
BMJ Open
|
October 17, 2020
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
Jonas S Heitmann, Juliane S Walz, Martin Pflügler, et al.
Annals of Hematology
|
January 23, 2020
Identification of CD318 (CDCP1) as novel prognostic marker in AML
Jonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, et al.
Cancers
|
September 28, 2021
CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
Joseph Kauer, Fabian Vogt, Ilona Hagelstein, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2022
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
Joseph Kauer, Melanie Märklin, Martin Pflügler, et al.
Frontiers in Immunology
|
March 16, 2026
Generation and preclinical characterization of a novel bispecific CD19-TCRgammadelta antibody for the treatment of B cell acute lymphoblastic leukemia
Joseph Kauer, Fabian Vogt, Sebastian Hörner, et al.
Scientific Reports
|
December 5, 2019
CD105 (Endoglin) as negative prognostic factor in AML
Joseph Kauer, Karolin Schwartz, Claudia Tandler, et al.
Hematological Oncology
|
January 21, 2023
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma
Joseph Kauer, Lilli Sophie Sester, Katharina Kriegsmann, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2020
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
Joseph Kauer, Sebastian Hörner, Lukas Osburg, et al.
BMC Cancer
|
November 22, 2023
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
Joseph Kauer, Emma P Freundt, Anita Schmitt, et al.
Frontiers in Immunology
|
September 28, 2020
Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia
Melanie Märklin, Alexander R Fuchs, Claudia Tandler, et al.
Page
of 4